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Ethyl pyruvate decreases sepsis-induced acute renal failure
and multiple organ damage in aged mice
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Ethyl pyruvate decreases sepsis-induced acute renal failure and
multiple organ damage in aged mice.
Background. Sepsis is a common cause of acute renal failure
(ARF). The incidence of sepsis increases dramatically after 50
years of age; however, most ARF studies are performed in
young mice.
Methods. We performed two common sepsis models, lipo-
polysaccharide (LPS) administration and cecal ligation punc-
ture (CLP) in aged mice. We developed a fully treated CLP
model in aged mice by treating mice with fluid resuscitation
and antibiotics.
Results. LPS induced renal injury in aged but not young
mice. However, volume resuscitation starting within 6 hours
decreased renal injury. We then used this fluid resuscitation
scheme, along with antibiotics, to develop a fully treated CLP
model in aged mice. Mice subjected to CLP developed func-
tional and histologic ARF and multiple organ damage. Treat-
ment with ethyl pyruvate, even when started 12 hours after
surgery, decreased serum creatinine, tubular damage, and mul-
tiple organ injury at 24 hours. Ethyl pyruvate decreased plasma
tumor necrosis factor- (TNF-), and kidney mRNA for
TNF, tissue factor, and plasminogen activator inhibitor-1
(PAI-1), and increased mRNA for urokinase-like plasminogen
activator.
Conclusion. CLP in aged mice causes functional and histo-
logic changes consistent with human ARF. A single dose of
ethyl pyruvate inhibits renal and multiple organ damage, and
is still effective when given 12 hours after surgery.
The mortality of acute renal failure (ARF) has re-
mained at about 45% over three decades, despite ad-
vances in supportive care, because patients have become
progressively older and have more comorbid conditions
[1, 2]. Sepsis is a contributing factor in 48% of patients
with ARF [3]. The mortality rate of ARF in septic pa-
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tients is 75%, and 45% in patients without sepsis [4].
Advanced age is a risk factor for mortality from sepsis
[5], ARF [6], and sepsis-induced ARF [2]. The outcome
remains poor in elderly patients with failure of two or
more organs [2]. Septic shock, characterized by hypoten-
sion, cardiovascular collapse, and multiple organ failure,
is treated with fluid resuscitation, antibiotics, and organ
support. Activated protein C decreases mortality from
sepsis [7]; however, there are no drugs to prevent or
treat sepsis-induced ARF [8, 9].
Treatment of sepsis-induced ARF has been stymied
by the lack of a good animal model. Lipopolysaccharide
(LPS)-induced systemic inflammation and cecal ligation
puncture (CLP)-induced polymicrobial infection models
are used commonly to screen drugs and study the patho-
genesis of sepsis. The usual LPS model does not have a
hyperdynamic phase and does not accurately reproduce
the response to therapeutics of human sepsis, perhaps
because of differences in the kinetics and magnitude of
cytokine targets such as tumor necrosis factor- (TNF-),
or because the model is too severe [10–13]. In the CLP
model, a small amount of fluid, given once to replace
postsurgical losses, promotes a hyperdynamic phase that
mimics human sepsis [14]. Renal dysfunction has oc-
curred in some [15–19] but not other [20, 21] studies;
however, the renal dysfunction may indicate volume
depletion, since the blood urea nitrogen (BUN) rises
more rapidly than creatinine [17] and histologic damage
was absent in one study [15]. Convincing histologic evi-
dence of CLP-induced ARF has only been reported in
one study [22]; however, the animals were only given
fluids to replace initial surgical losses, and did not receive
antibiotics. Unfortunately, neither LPS nor CLP model
causes ARF with histologic evidence of injury under
conditions of adequate volume and antibiotic resuscita-
tion that are the mainstays of treatment for human sepsis
[8, 12]. A clinically relevant sepsis-induced ARF model
that includes both volume and antibiotic resuscitation
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would be useful for testing new drugs and determining
the pathogenesis of disease.
Several agents reduce CLP mortality when given at
or soon after sepsis (for example, see [23]). In contrast,
ethyl pyruvate reduces mortality after LPS and CLP
sepsis, even when started 24 hours after CLP surgery
[24]. Ethyl pyruvate also preserves mucosal histology
and permeability after mesenteric ischemia/reperfusion
[25], and survival and intestinal damage after hemor-
rhagic shock [26]. Ethyl pyruvate scavenges reactive oxy-
gen species (ROS), down-regulates proinflammatory cy-
tokines [interleukin-1 (IL-1), IL-6, and TNF-] both in
vitro and in vivo, inhibits high mobility group box 1
protein (HMGB1), a late mediator of sepsis, and de-
creases the activation of p38 mitogen-activated protein
kinase (MAPK) and nuclear factor-B (NF-kB) [24, 27,
28]. However, it is not known if ethyl pyruvate can pro-
tect against organ dysfunction, including ARF, when ad-
ministered following sepsis.
Therefore, we developed a model of sepsis-induced
ARF in aged mice employing a clinically relevant volume
and antibiotic resuscitation strategy and studied the tem-
poral expression of organ dysfunction and key mediators.
We tested if ethyl pyruvate decreases sepsis-induced re-
nal and multi-organ injury in our new model. We studied
the action of ethyl pyruvate on inflammatory and coagu-
lation/hemostasis mediators, because numerous pathways
may interact in concert to produce organ failure [29].
METHODS
Animals
Animal care followed National Institutes of Health
(NIH) criteria for the care and use of laboratory animals
in research. Young (7 to 8 weeks) and aged (42 to44
weeks) male C57BL/6 mice (NIH, Frederick, MD, USA)
had free access to water and chow (NIH-07 Rodent
Chow) (Zeigler Bros., Gardners, PA, USA) before and
after surgery. Aged mice were housed individually.
LPS-induced ARF
A single dose of 0.08 mg/kg LPS (O11:B4) (Sigma
Chemical Co., St. Louis, MO, USA) in 0.3 mL of sterile
normal saline was administrated intravenously via the
tail vein. In some animals, 1.5 mL of 3/4 normal saline
was given at 0, 6, or 18 hours after LPS injection, and
then every 12 hours. Animals were sacrificed at 48 hours
for measurement of serum creatinine.
Polymicrobial CLP sepsis-induced ARF
Mice were anesthetized with 100 mg/kg ketamine, 10
mg/kg xylazine, and 1 mg/kg acepromazine intramuscu-
larly. After laparotomy, a 5-0 silk ligature was placed 5
mm from the cecal tip. The cecum was punctured twice
with a 21-gauge needle and gently squeezed to express
a 1 mm column of fecal material. In sham-operated ani-
mals, the cecum was located, but neither ligated nor
punctured. The abdominal incision was closed in two
layers with 6-0 nylon sutures. After surgery, 1 mL of
prewarmed normal saline was given intraperitoneally.
All animals received a broad-spectrum antibiotic (imi-
penem/cilastatin; 25 mg/kg subcutaneously) [30] and 1.5
mL of 3/4 normal saline was administered at 6 and 18
hours after surgery by subcutaneous injection. Imipenem/
cilastatin was selected because it has been used by several
other laboratories in the young mouse CLP model and
has been shown to increase survival more than triple
antibiotic therapy [24, 30, 31]. At the time of sacrifice,
blood was collected from abdominal aorta for measure-
ment of blood chemistries. The kidneys were harvested
for histologic and mechanistic studies. In a very small
pilot study, CLP surgery in young mice produced a wide
range of creatinine values at 24 hours without much
histologic evidence of renal damage (data not shown).
Therefore, subsequent studies were performed in aged
mice.
Survival study
Survival after surgery was assessed every 6 hours
within the first 48 hours and then every 8 hours for 4
days. Antibiotic injection and fluid resuscitation were
started 6 hours after CLP by subcutaneous injection, and
then repeated every 12 hours for 4 days.
Ethyl pyruvate treatment protocol
Animals received 0.4 mL of Ringer’s lactate (130
mmol/L Na, 4 mmol/L K, 2.7 mmol/L Ca2, 109
mmol/L Cl–, and 28 mmol/L lactate) or a similar volume
of freshly made Ringer’s ethyl pyruvate where ethyl pyr-
uvate (Sigma Chemical Co.) was substituted for sodium
lactate. A single dose was injected intraperitoneally at
0, 6, or 12 hours after CLP surgery. The dose of ethyl
pyruvate was based upon that used by Ulloa et al [24].
Blood chemistries and serum TNF- measurements
Serum levels of BUN, aspartate transaminase (AST),
alanine transaminase (ALT), amylase, creatine kinase
(CK), and lactate dehydrogenase (LDH) were measured
using an autoanalyzer (Hitachi 917, Boehringer Mann-
heim, Indianapolis, IN, USA). Serum creatinine was
measured by a picric acid-based colorimetric kinetic au-
toanalyzer (Astra 8 autoanalyzer; Beckman Instruments,
Fullerton, CA, USA). However, picric acid methods
can greatly overestimate serum creatinine in mice [32];
therefore we also measured serum creatinine by high-
performance liquid chromatography (HPLC) adapted
from Dunn and Sharma (Dr. Kumar Sharma, Thomas
Jefferson University, personal communication, 2003),
and Johns et al [33]. Acetonitrile was added to serum,
centrifuged, and the supernatant fraction was dried, re-
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suspended in 5 mmol/L sodium acetate, pH 5.1, and
chromatographed isocratically on a PRP-X200 cation ex-
change column (Hamilton, Reno NV, USA) and de-
tected by ultraviolet absorbance at 234 nm (Agilent
Technologies, Palo Alto, CA, USA). TNF-was assayed
by enzyme-linked immunosorbent assay (ELISA) (Quan-
tikineM, R&D Systems, Inc., Minneapolis, MN, USA).
The minimum detectable concentration was less than
5 pg/mL.
Histologic examination
The 10% formalin-fixed, paraffin-embedded kidney
sections were stained with periodic acid-Schiff reagent
(PAS) or naphthol AS-D chloroacetate esterase (Sigma
Chemical Co.). Histologic changes in the cortex and in
the outer stripe of the outer medulla (OSOM) were
assessed by quantitative measurements of tissue damage.
Tubular damage was defined as tubular epithelial swell-
ing, loss of brush border, vacuolar degeneration, necrotic
tubules, cast formation, and desquamation. The degree
of kidney damage was estimated at 400 magnification
using five randomly selected fields for each animal by the
following criteria: 0, normal; 1, areas of damage25% of
tubules; 2, damage involving 25% to 50% of tubules; 3,
damage involving 50% to 75% of tubules; 4, 75% to
100% of the area being affected.
Western blot analysis for Cyr61
Cyr61 expression in the kidney was measured as de-
scribed previously [34].
Measurement of mRNA abundance by reverse
transcription-polymerase chain reaction
Reverse transcription-polymerase chain reaction (RT-
PCR) was performed to examine malate dehydrogenase
(MDH) (all primers shown 5 to 3) forward, GGTCAT
TGTTGTGGGAAACC; reverse, TCGACACGAACT
CTCCCTCT; plasminogen activator inhibitor-1 (PAI-1)
forward, CAGAGGTGGAAAGAGCCAGA; reverse,
AGCGATGAACATGCTGAGG; tissue factor forward,
GTGCAGGCATTCCAGAGAA; reverse, TGGGAC
AGAGAGGACCTTTG; tissue-type plasminogen acti-
vator (tPA) forward, TGATGGCTCAGAGCAACAAG;
reverse, GCCAGGGTTGCACTAAACAT; urokinase-
type plasminogen activator (uPA) forward, TTGTCCA
AGAATGCATGGTG; reverse, GCTGCTCCACCTC
AAACTTC; and TNF- forward, GAACTGGCAGAA
GAGGCACT; reverse, AGGGTCTGGGCCATAGA
ACT) mRNA abundance. Briefly, total RNA was ex-
tracted from the kidney by using TRIzol (Invitrogen,
Carlsbad, CA, USA), cDNA was generated SuperScript
II (Invitrogen), and amplified by PCR primers. The PCR
conditions were Mg 2.5 mmol/L, annealing temperature
57C (59C for uPA), and 35 cycles. These conditions
resulted in a single band with a linear relationship be-
tween cDNA and PCR product. We normalized to
mouse MDH in parallel PCR reactions. The PCR prod-
ucts were separated by electrophoresis and quantitated
by NIH-Image.
Statistical analysis
All data are expressed as means  SE. Differences
between groups were examined for statistical significance
by analysis of variance (ANOVA) with a multiple com-
parison correction (StatView 4.5, Berkeley, CA, USA;
or SigmaStat 2.0, SPSS, San Rafael, CA, USA). A P
value 0.05 was accepted as statistically significant.
RESULTS
Effect of volume resuscitation in a LPS-induced
ARF model
Injection of 0.08 mg LPS caused a time-dependent
transient increase in BUN and creatinine (measured by
picric acid) in aged mice but not in young mice (Fig.
1A). Since the initial treatment of human sepsis is volume
replacement, we restored volume with 1.5 mL of 3/4
normal saline every 12 hours, sufficient to prevent weight
loss and keep plasma sodium constant. Volume repletion
starting at the time of LPS injection ameliorated the
increase in creatinine. Since the diagnosis of sepsis is
often delayed, we determined the window of opportunity
of volume repletion. Volume repletion starting at 6 hours
but not 18 hours after LPS inhibited renal injury (Fig.
1A). Thus, aged mice are more susceptible to LPS-
induced injury. However, the LPS-induced injury was
unexpectedly reversed by fluid administration, which is
not a feature of human sepsis-induced ARF [8].
Characterization of the volume- and antibiotic-treated
CLP model in aged mice
Since aged mice were more susceptible to LPS-induced
ARF, we evaluated the CLP model in aged mice. To
make the model more realistic, we administered both
volume and antibiotic treatment every 12 hours starting
at 6 hours after surgery to mimic the time needed to
detect sepsis in humans. Under these conditions, body
weight increased by 7%, and the survival was 100% at
24 hours, 43% at 48 hours, and 14% at 72 hours (Fig.
1B). Therefore, we set the end point of study at 24 hours
to examine the mechanism of sepsis-induced ARF.
Aged mice given volume and antibiotic treatment after
CLP had multiple organ injury (Fig. 2). AST, ALT, and
LDH were increased as early as 6 hours after CLP, and
increased further at 24 hours. The level of CK was also
rapidly increased after CLP surgery; however, the tran-
sient increase at 11⁄2 hours was also detected in the sham-
surgery group and likely a result of the intramuscular
anesthetic. CK increased above sham levels at 6 hours,
and continued to rise at 24 hours. In contrast, release of
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Fig. 1. Effect of volume resuscitation. (A ) Volume replacement inhib-
its lipopolysaccharide (LPS)-induced acute renal failure (ARF) in aged
mice. Aged mice were injected intravenously with 0.08 mg LPS. In
some animals, volume replacement was started at 0, 6 or 18 hours, and
continued every 12 hours. Animals were sacrificed at 48 hours for
measurement of creatinine. Creatinine values are also shown for normal
aged mice, sham-injected aged mice, and young mice given LPS but
not fluids. Values are mean  SE (N 	 4 to 10 per group). *P  0.05
vs. sham; P  0.05 vs. aged without fluid group. (B ) Survival after
antibiotic- and volume-resuscitated cecal ligation puncture (CLP) sepsis
in aged mice. Aged mice were subjected to CLP. Antibiotic and fluid
resuscitation were started at 6 hours after surgery, and then given every
12 hours. Survival rates were monitored for 96 hours. Closed circles
and solid line indicates CLP group (N 	 15). Open diamonds and
dashed line indicates sham group (N 	 10).
serum amylase was delayed; amylase remained at basal
levels during the first 12 hours and significantly increased
at 24 hours after CLP. To confirm that these serologic
tests reflected actual tissue damage, we performed histo-
logic analysis in a parallel set of mice. We found moder-
ately severe liver injury consisting of swollen and vacuo-
lated hepatocytes with nuclear swelling, but no necrosis
or inflammation. In the lung, we saw patchy congestion,
hemorrhage, and inflammation (data not shown). This
model reproduces the multiorgan damage following CLP
in young mice and rats [30, 35], and the hepatic, pancre-
atic, and muscle/myocardial damage in human sepsis
[36–38].
CLP sepsis-induced ARF
CLP sepsis caused time-dependent increases in mark-
ers of renal dysfunction (Fig. 3). BUN was significantly
increased as early as 3 hours after surgery, whereas the
rise in creatinine was delayed until 12 and 24 hours after
surgery. In contrast to previous nonfluid-replete CLP
models where the BUN/creatinine ratio increases [17],
both BUN and creatinine increased in parallel in our
fluid-replete model. This suggests a lack of significant
volume depletion in this model. Studies by Myers et
al [35] published in 1985 noticed that measurement of
creatinine by picric acid overestimates serum creatinine
concentration in mice. Therefore, we examined the levels
of serum creatinine by HPLC technique using serum
samples obtained from the same CLP mice. As shown
Figure 3C, the level of HPLC creatinine in normal aged
mice was 0.09  0.01 mg/dL, which was approximately
one third that of picric acid creatinine. The increase in
HPLC creatinine paralleled that of picric-acid creatinine;
thus, we detected a significant increase in HPLC creati-
nine at 12 hours (0.24  0.02 mg/dL, P  0.01 vs. 0 hour)
and a further increase at 24 hours (0.37  0.07 mg/dL,
P 0.01 vs. 0 hour) after CLP. Creatinine was measured
by HPLC in subsequent experiments.
Time course of tubular damage in CLP-ARF
At 6 hours after CLP, histologic examination of PAS-
stained sections revealed focal tubular epithelial swell-
ing, shortened brush border, and vacuolar degeneration
in both the cortex and OSOM (Fig. 4B). At 12 to 24 hours
after surgery, more extensive tubular damage was seen
(Fig. 4 C and F) in both areas. Unlike the ischemic or
nephrotoxin-induced mouse ARF models [39, 40], we did
not detect tubular necrosis, vascular congestion, or exces-
sive cast formation. Leukocyte accumulation, while occa-
sionally present, was not a prominent feature (Fig. 4E).
Effect of CLP sepsis on renal Cyr61 expression
and serum TNF-
We recently demonstrated that Cyr61 was rapidly in-
duced in the kidney and secreted into the urine after
ischemia/reperfusion injury, but not after volume deple-
tion [34]. Therefore, we measured Cyr61 to investigate
the timing of tubular injury in polymicrobial sepsis-
induced ARF. Cyr61 expression in the kidney was de-
tected at 6 hours after surgery (a time at which serum
creatinine was normal) (Fig. 3C), and sustained for at
least 24 hours (Fig. 4G). Thus, renal injury occurs even
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Fig. 2. Time course of multiple organ injury.
Antibiotic- and volume-resuscitated cecal li-
gation puncture (CLP) or sham surgery was
performed as in Figure 1. Animals were sacri-
ficed at the indicated time and blood samples
were collected for measurement of serum
aspartate transaminase (AST), alanine trans-
aminase (ALT), amylase, creatine kinase (CK),
and lactate dehydrogenase (LDH) (N 	 5 to
6 per group). Closed circles and solid lines
indicate CLP group. Open diamonds and
dashed lines indicate sham group. *P  0.05
vs. 0 hour.
before an increase in serum creatinine can be detected
(Fig. 3C).
Both LPS and CLP sepsis induce a systemic inflamma-
tory response, although the degree of activation is quite
different [10]. We measured the levels of serum TNF-
by ELISA (Fig. 5). Aged CLP mice had a biphasic in-
crease in TNF-, with peaks at 3 and 24 hours. In con-
trast, aged mice injected with LPS had a more rapid,
transient, and 20-fold larger increase in TNF- than de-
tected in the CLP model. Thus, the proinflammatory
stimulus in aged CLP mice is less intense than following
LPS, similar to that reported in young mice [10], but it
also occurs much later.
Effects of ethyl pyruvate on CLP-induced multiple
organ damage and ARF
Ulloa et al [24] reported that ethyl pyruvate greatly
decreased mortality in an antibiotic- (but not fluid-)
treated CLP model in young mice, even when started
24 hours after CLP. However, they did not measure renal
function or indices of multiple organ damage. Therefore,
we tested ethyl pyruvate in our volume-replete model
of polymicrobial sepsis in aged mice; the same volume
of Ringer’s lactate was given as a control. As shown
Figure 6, a single dose of either 8 (thin gray line) or 40
mg/kg (thick gray line) ethyl pyruvate immediately after
surgery partially inhibited muscle (CK), hepatic, and
pancreatic (amylase) injury at 24 hours. Delayed admin-
istration of ethyl pyruvate at 6 and 12 hours had similar
protective effects; except that delay of ethyl pyruvate
for 12 hours did not alter AST.
The effects on renal function were more striking. A
single dose of either 8 or 40 mg/kg of ethyl pyruvate
after surgery significantly prevented the renal injury as
measured by BUN or HPLC creatinine (Fig. 7) (8 mg/kg,
0.17  0.02 mg/dL; 40 mg/kg, 0.14  0.02 mg/dL vs.
Ringer’s lactate, 0.33  0.07 mg/dL). The higher dose
of ethyl pyruvate significantly reduced the renal injury
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Fig. 3. Time course of acute renal failure (ARF) after antibiotic- and
volume-resuscitated cecal ligation puncture (CLP) sepsis in aged mice.
Mice were treated as in Figure 2. Animals sacrificed at indicated times
for measurement of serum creatinine by picric acid (A) or high-perfor-
mance liquid chromatography (HPLC) method (C), and BUN (B).
Data displayed as in Figure 2. *P  0.05 vs. 0 hour.
even when delayed until 6 or 12 hours after surgery
(HPLC creatinine, 6 hours, 0.13  0.01 mg/dL; 12 hours,
0.17  0.03 mg/dL). Administration of 40 mg/kg ethyl
pyruvate at either 0, 6, or 12 hours after CLP significantly
reduced the tubular damage measured at 24 hours in
both the cortex and OSOM (Figs. 4D and 7B).
Effect of ethyl pyruvate on serum TNF-
To begin to investigate the mechanisms of action of
ethyl pyruvate, we examined its effects on the systemic
proinflammatory response to sepsis. The sepsis-induced
increase in serum TNF- at 24 hours was inhibited by
both 8 and 40 mg/kg of ethyl pyruvate administered at
the time of surgery (Fig. 8A). Delay of ethyl pyruvate
for either 6 or 12 hours also decreased serum TNF- at
24 hours (Fig. 8A).
Effects of ethyl pyruvate on mRNA for kidney
coagulation and fibrinolytic factors
There is important cross-talk between inflammation
and coagulation pathway in sepsis. Activated protein C,
which reduces mortality in human sepsis, modulates both
inflammation and coagulation pathways [7, 41]. There-
fore, we examined the expression mRNA for of key
fibrinolytic coagulation factors in the kidney. As shown
Figure 8B, CLP increased the expression of mRNA for
TNF-, tissue factor, PAI-1, and tPA. In contrast, the
mRNA expression of uPA was decreased at 12 hours.
We found that a single 40 mg/kg dose of ethyl pyruvate
injected after surgery inhibited the induction of mRNA
for TNF-, tissue factor, PAI-1, and tPA, and also pre-
vented the decrease in uPA mRNA abundance at 12
hours after surgery. Therefore, the ratio of PAI-1/uPA
but not PAI-1/tPA was returned to basal levels by ethyl
pyruvate at 12 hours after CLP (Fig. 8C). Taken together
with the serum TNF- findings, our data suggest that
ethyl pyruvate has effects on both proinflammatory and
coagulation/fibrinolytic pathways.
DISCUSSION
We initially studied a LPS infusion model because of
its simplicity; however, volume replacement with saline
prevented and could also treat acute renal injury (Fig.
1A). Since human sepsis-induced ARF is not easily re-
versed with fluids [8], we (1) developed a new mouse
model of sepsis-induced ARF that mimics the human
disorder, (2) used the model to demonstrate the effects
of a novel intervention, ethyl pyruvate, to inhibit sepsis-
induced ARF even when administered 12 hours after
induction of sepsis, and (3) showed that ethyl pyruvate
acts on a previously unsuspected coagulation/hemostatic
pathway.
Model of sepsis-induced ARF that mimics
the human disease
We developed a new model of sepsis-induced ARF
based upon the polymicrobial CLP model, but with two
distinctive features: (1) appropriate volume and antibi-
otic resuscitation, and (2) use of aged mice. As in the
standard CLP model in young mice, animals were given
an intra-abdominal infection and a small amount of fluid
resuscitation immediately after surgery to foster a hyper-
dynamic phase that is characteristic of early human sepsis
[14, 42]. Nevertheless, the animals may have been slightly
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Fig. 4. Time course of renal histologic
changes. Kidney sections were stained with
either periodic acid-Schiff (A to D ) or naph-
thol AS-D chloroacetate esterase (E ). Typical
histology in sham-treated animals at 24 hours
(A) or cecal ligation puncture (CLP) animals
at 6 hours (B) and 24 hours (C) are shown.
Typical histology in animals treated with ethyl
pyruvate at 24 hours (D). Arrows, esterase-
positive cells (original magnification,250 (A
to D),400 (E). (F ) Time course of the tubu-
lar damage. The tubular damage score (see
Methods section) was measured in the cortex
(right panel) or the outer stripe of the outer
medulla (OSOM) (left panel). Values are
mean  SE (N 	 5 to 6 per group). *P  0.05
vs. sham. (G ) Time course of renal Cyr61
expression. Renal Cyr61 measured at indicated
times (hours) after CLP. N, normal; S, sham;
and P, positive control for Cyr61.
Fig. 5. Time course of serum tumor necrosis factor- (TNF-) expres-
sion in lipopolysaccharide (LPS) and cecal ligation puncture (CLP)
models in aged mice. Mice were treated as in Figure 2. At the indicated
times, mice were sacrificed and the sera were collected (N 	 5 to 6
per time point). Serum levels TNF- were measured by enzyme-linked
immunosorbent assay (ELISA). Inset: Similar protocol in aged mice
injected with LPS (N	 4 per group). Note dramatically different y-axis
scales. *P  0.05 vs. 0 hour.
volume depleted after surgery, since BUN was increased
at 3 hours without a corresponding increase in creatinine
(Fig. 3). Primate and porcine CLP models generally in-
clude fluid administration from the time of sepsis; contin-
uous intravenous fluid replacement improves survival in
a rat CLP model [43]. However, the typical mouse CLP
model does not include additional volume repletion and
antibiotic treatment that is standard care for septic pa-
tients [8]. In our new model, the full volume and antibi-
otic resuscitation was not started until 6 hours after sur-
gery to simulate a short window of undiagnosed sepsis.
We used a broad-spectrum antibiotic regime employed
by others [30]. We chose a volume resuscitation schedule
that inhibited LPS-induced renal damage (Fig. 1A) and
increased body weight by 7% to mimic the fluid overload
often present in hypotensive intensive care unit patients.
The second unique feature of the model was the use of
aged mice. We used aged mice because they more closely
match the age distribution of sepsis-induced ARF and
because the elderly are more prone to sepsis-induced
ARF [2]. We also chose aged mice because we had diffi-
culty obtaining reproducible renal injury in a small pilot
study in young mice. Furthermore, aged mice are more
prone to LPS-induced mortality [44], LPS-induced ARF
(Fig. 1A), stress, and LPS-induced thrombosis, and glo-
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Fig. 6. Effects of ethyl pyruvate on multiple
organ injury in antibiotic and volume resusci-
tated cecal ligation puncture (CLP) sepsis.
Aged mice were treated as in Figure 2. A
single dose of Ringer’s lactate vehicle or 8 or
40 mg/kg ethyl pyruvate was injected at 0,
6, or 12 hoursr after CLP. Serum aspartate
transaminase (AST), alanine transaminase
(ALT), amylase, creatine kinase (CK), and
lactate dehydrogenase (LDH) were measured
(N 	 10 to 13 per group). *P  0.05 vs. sham.
P  0.05 vs. Ringer’s lactate.
merular fibrin deposition in part due to enhanced induc-
tion of NF-kB, TNF-, and PAI-1 mRNA induction in
the kidney [45, 46]. Since this hyperresponsiveness to
LPS was reduced in older PAI-1–deficient mice, some
of the age effect is likely due to changes in PAI-1 [45].
Despite adequate volume and antibiotic resuscitation,
the aged animals developed progressive multiorgan in-
jury first detected at 6 hours after sepsis, with initial
changes in liver and muscle as previously described [47],
and later pancreatic injury (Fig. 2). The kidney injury
was delayed; whereas we detected a rise in the tubular
injury marker Cyr61 at 6 hours, serum creatinine did not
rise above sham-operated controls until 12 hours (Figs.
3C and 4G). The mortality rate was 60% at 48 hours and
86% at 72 hours, which is similar to the 75% mortality
reported in human sepsis-induced ARF [4]. The tempo-
ral sequence of early muscle and liver injury, with de-
layed renal injury, reproduces the temporal sequence of
human sepsis, where renal injury is often last in a series
of organ failures.
A major new feature of this model is histologic evi-
dence of ARF, which has been detected in only one
nonfluid-replete CLP study [22]. We documented renal
injury by three independent methods, including a new
and more accurate measurement of serum creatinine by
HPLC that detects smaller changes in creatinine from
baseline than are possible with the picric acid–based
method. First, we found parallel elevations in BUN and
creatinine, suggestive of renal injury rather than volume
depletion. Previous models have either failed to find
increases in creatinine [20, 21], or the change in BUN
was much greater than that of creatinine, suggesting a
component of volume depletion [17]. Second, we saw
vacuolization of the proximal tubule throughout the cor-
tex and OSOM. This vacuolated appearance is similar
to the intracellular edema, loss of cell membrane, and
mitochondrial swelling seen in the kidneys of young rats
subjected to CLP without antibiotics or fluid replace-
ment [22]. We did not detect necrosis of the proximal
straight tubule, erythrocyte accumulation, or extensive
cast formation typical of ischemic or nephrotoxic injury
[39, 40]. The histologic appearance of human sepsis-
induced ARF is poorly described. Biopsy is not routinely
performed for the diagnosis of ARF, thus severely lim-
iting the understanding of the process. Unfortunately,
the kidney is subject to rapid autolysis, with changes
that mimic those seen in ARF, which may limit their
interpretation. Two “immediate” autopsy studies have
been performed in patients who died of sepsis. Sato et al
[48] detected only modest histologic and ultrastructural
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Fig. 7. Effects of ethyl pyruvate on acute renal failure (ARF) following
cecal ligation puncture (CLP) sepsis. Animals treated as in Figure 6,
and were sacrificed at 24 hours (N 	 10 to 13 per group). (A ) Blood
urea nitrogen (BUN) and high-performance liquid chromatography
(HPLC) creatinine. (B ) The tubular damage score was measured in
the cortex and the outer stripe of the outer medulla (OSOM). *P 
0.05 vs. sham. P  0.05 vs. Ringer’s lactate.
changes in immediate autopsy patients who died 4 to 50
days after onset of sepsis. They found increased vacuoli-
zation and flattening of the brush border membrane. A
recent study by Hotchkiss et al [49] did not detect either
necrosis or apoptosis in the kidneys of septic patients
at autopsy; however, electron microcopy was not per-
formed. Finally, we detected an increase in the renal
tubular injury marker Cyr61 that we recently reported
to increase in the kidney at 1 hour after renal ischemia/
reperfusion but not after volume depletion [34]. Thus,
we detected functional, histologic, and surrogate marker
evidence of renal injury. Taken together, this new model
Fig. 8. Effects of ethyl pyruvate on mediators after cecal ligation punc-
ture (CLP) sepsis. Mice were subjected to antibiotic and volume resusci-
tated CLP sepsis. (A ) Mice were treated as in Figure 6, and sacrificed
at 24 hours. Tumor necrosis factor- (TNF-) measured by enzyme-
linked immunosorbent assay (ELISA) (N 	 5 to 6 per group). (B ) A
single dose of Ringer’s lactate (RL) or 40 mg/kg ethyl pyruvate (EP)
was injected after surgery, and mice were sacrificed at 12 hours to
analyze the mRNA expression in the kidney using reverse-transcription-
polymerase chain reaction (RT-PCR) analysis. (C ) Semiquantitative
analysis of RT-PCR (N 	 6 per group). *P  0.05 vs. sham. P 
0.05 vs. Ringer’s lactate. Abbreviations are: TF, tissue factor; PAI-1,
plasminogen activator inhibitor-1; tPA, tissue-type plasminogen activa-
tor; uPA, urokinase-type plasminogen activator; MDH, malate dehydro-
genase.
of volume and antibiotic resuscitated polymicrobial sep-
sis in aged mice shows many features in common with
human sepsis, including sepsis-induced ARF.
It is interesting that we could detect subtle renal injury
by increases in Cyr61 protein (Fig. 4G) and renal pathol-
ogy score in the outer stripe at 6 hours after injury (Fig.
4F), yet serum creatinine did not increase until 12 hours
after injury (Fig. 3C). Dilution of creatinine at 6 hours
by volume expansion, a frequent explanation for the
inability to detect early renal injury using serum creati-
nine [1], is unlikely since the animals received fluid to
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replace surgical losses and the BUN was not similarly
suppressed (Fig. 3B). Alternatively, renal cellular injury
might occur before glomerular filtration rate (GFR) de-
clines, suggesting that the tubules are injured before the
microvasculature. In either case, better circulating or
urinary markers are needed to detect early renal injury
in the face of sepsis.
Effects of ethyl pyruvate on sepsis-induced ARF
Ethyl pyruvate has been shown to decrease mortality
in both the LPS and CLP models and is effective even
when given 24 hours after CLP sepsis [24]. We have
extended these results to show that ethyl pyruvate inhib-
its multiple organ injury in kidney, muscle, and pancreas
(Figs. 6 and 7). Ethyl pyruvate still protected against
renal and muscle injury even when treatment is started
12 hours after surgery; there was also a suggestion of
pancreatic protection (not statistically significant). The
renal injury was documented by suppression of sepsis-
induced elevations of BUN, creatinine (Fig. 7A) and
tubular damage score, especially in the OSOM (Fig. 7B).
The amount of protection was consistently 60% to 80%
for HPLC and tubular injury score, without much change
with delayed treatment. This wide therapeutic window,
at least 12 hours for sepsis-induced ARF and 24 hours
for sepsis-induced mortality [24], is longer than that of
antibodies to triggering receptor expressed in myeloid
cells (TREM) (4 hours) [23] or C5a (12 hours) [35], and
similar to antibodies to HMG-B1 (24 hours) [27, 50].
Thus, ethyl pyruvate may be a treatment for both sepsis
and sepsis-induced renal and multiorgan injury. This pro-
longed window of opportunity may be important clini-
cally because of the difficulty in the early detection of
sepsis and sepsis-induced ARF.
Mechanisms of action
The molecular targets and mechanisms of ethyl pyr-
uvate are unknown. Whereas ethyl pyruvate was origi-
nally considered an ROS scavenger, recent data in hem-
orrhagic and LPS shock models suggest rather that ethyl
pyruvate inhibits proinflammatory cytokines and HMG-
B1. For example, ethyl pyruvate inhibits LPS-stimulated
TNF- production from macrophages in vitro and plasma
TNF- elevation after LPS injection in vivo, perhaps via
inhibition of NF-kB and p38 MAPK signal transduction
pathways [24, 28, 51]. We found that ethyl pyruvate in-
hibited circulating TNF- measured at 24 hours (Fig.
8A), even when ethyl pyruvate was started 12 hours after
surgery. If ethyl pyruvate was started 12 hours after
CLP, the level of TNF- at 24 hours was similar to that
obtained when ethyl pyruvate was administered 12 hours
after CLP (Fig. 5). This suggests that delayed ethyl pyr-
uvate treatment inhibited TNF- production even after
the proinflammatory stimulus was underway. Ethyl pyr-
uvate also modestly inhibited renal TNF-mRNA abun-
dance, suggesting that ethyl pyruvate may act on non-
renal organs (liver, spleen, etc.), where most of the
circulating TNF- is made in sepsis. However, the impor-
tance of this effect of ethyl pyruvate on TNF- to the
overall pathogenesis of sepsis is uncertain. Anti-TNF-
antibody therapy does not decrease mortality in CLP
mice, and even increases overall mortality in human stud-
ies, perhaps because TNF- prevents the spread of a
localized infection [10, 52]. In contrast, recent studies
suggest that TNF- may be an important mediator of
renal injury [53]. Inhibition of TNF- by genetic or anti-
body techniques, or deletion of the TNF- receptor-1
inhibits renal injury following ischemia, cisplatin admin-
istration, and LPS-induced ARF [54–57]. A subgroup
analysis of the INTERSEPT study [58] found that anti-
TNF- antibodies significantly decreased sepsis-induced
ARF. Thus, TNF- may be an important mediator of
renal damage. TNF- is usually synthesized at sites of
injury and amplifies the inflammatory response; the re-
sulting inflammation may injure surrounding tissues.
However, renal inflammation is limited in the CLP
model; neutrophils are present, but not prominent, in
agreement with previous observations that renal myelo-
peroxidase is not elevated [19] or only elevated twofold
after CLP, despite large increases in liver and lung my-
eloperoxidase [15]. TNF- is more likely to act directly
on the kidney. Kidney-specific deletion of the TNF re-
ceptor-1 decreases LPS-induced ARF [56], supporting a
localized role for TNF- toxicity, possibly acting directly
on tubular cells. Taken together, the studies suggest that
ethyl pyruvate may protect against renal injury, in part,
via its inhibition of TNF-.
Sepsis causes profound derangements in the coagula-
tion/hemostatic system, including consumption of coagu-
lation factors, increased coagulation/hemostatic activity,
and reduced fibrinolysis [29]. The positive result of a re-
cent clinical trial of activated protein C [7] suggests the
pathophysiologic importance of the coagulation/hemo-
static system in human sepsis. We found that sepsis de-
creased mRNA abundance for uPA and increased tissue
factor and PAI-1 mRNA (Fig. 8B), which would tip
the balance toward increased coagulation and reduced
fibrinolysis, similar to previously studied effects of LPS
[59]. Ethyl pyruvate reversed these changes, perhaps re-
storing the renal hemostatic system to normal. Taken
together, this suggests that ethyl pyruvate has a broader
mechanism of action than previously suspected, with ef-
fects on proinflammatory cytokines and potential hemo-
static pathways. Two other agents, activated protein C
and c5a antibodies, that protect against sepsis also inhibit
inflammatory and coagulation pathways [7, 41, 60].
CONCLUSION
We have introduced a novel volume- and antibiotic-
treated aged mouse model of sepsis-induced ARF that
Miyaji et al: Ethyl pyruvate inhibits sepsis-induced ARF1630
mimics many aspects of human sepsis. This model should
be useful for screening therapeutic agents and determin-
ing mechanisms of disease pathogenesis and protection.
We then used the model to establish that ethyl pyruvate
inhibits sepsis-induced renal and multiorgan damage,
even when started 12 hours after surgery. Ethyl pyruvate
protects against renal injury, in part, by inhibiting dysreg-
ulated inflammatory and coagulation/hemostatic path-
ways. Thus, it has the potential to simultaneously inhibit
both early (TNF-, hemostatic) and late (HMG-B1) me-
diators in sepsis. Ethyl pyruvate may hold promise in
clinical settings, since it can prevent the initiation and
protect the progressive phase of sepsis-induced ARF.
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